Bristol Myers Squibb

News

BMS' deucravacitinib psoriasis pill outperforms Amgen's Otez...

Bristol-Myers Squibb could be on the verge of a major coup in psoriasis after its deucravacitinib pill outperformed Amgen’s rival Otezla.

News

3d rendering robot working with digital display

BMS joins forces with insitro to develop neurodegenerative t...

insitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies for amyotrophic lateral sclerosis (ALS) and frontotempo

News

FDA kicks off review of second kidney cancer combo based on ...

Bristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy that will help defend its first-line kidney cancer franchise.

News

Scotland backs two myeloma drugs turned down by NICE in Engl...

A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) backed NHS use of two drugs previously turned down by NICE in England.<

News

Data sets up ulcerative colitis expansion for BMS’ MS drug Z...

Bristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – and new data in ulcerative colitis suggests they could climb

News

BMS bulks up in cardio with $13.1bn takeover deal for MyoKar...

Bristol-Myers Squibb has said it will buy biotech MyoKardia in a $13.1 billion takeover that marks a step up in its development of cardiovascular drugs.

BMS' deucravacitinib psoriasis pill outperforms Amgen's Otez...

BMS joins forces with insitro to develop neurodegenerative t...

FDA kicks off review of second kidney cancer combo based on ...

Scotland backs two myeloma drugs turned down by NICE in Engl...

Data sets up ulcerative colitis expansion for BMS’ MS drug Z...

BMS bulks up in cardio with $13.1bn takeover deal for MyoKar...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks